Nitric oxide donor-based cancer therapy: advances and prospects
Z Huang, J Fu, Y Zhang - Journal of medicinal chemistry, 2017 - ACS Publications
The increasing understanding of the role of nitric oxide (NO) in cancer biology has
generated significant progress in the use of NO donor-based therapy to fight cancer. These …
generated significant progress in the use of NO donor-based therapy to fight cancer. These …
Advanced nitric oxide donors: Chemical structure of NO drugs, NO nanomedicines and biomedical applications
Y Yang, Z Huang, LL Li - Nanoscale, 2021 - pubs.rsc.org
Nitric oxide (NO), as an endogenous diatomic molecule, plays a key regulatory role in many
physiological and pathological processes. This diatomic free radical has been shown to …
physiological and pathological processes. This diatomic free radical has been shown to …
Dual intratumoral redox/enzyme‐responsive NO‐releasing nanomedicine for the specific, high‐efficacy, and low‐toxic cancer therapy
X Jia, Y Zhang, Y Zou, Y Wang, D Niu, Q He… - Advanced …, 2018 - Wiley Online Library
Chemotherapy suffers numbers of limitations including poor drug solubility, nonspecific
biodistribution, and inevitable adverse effects on normal tissues. Tumor‐targeted delivery …
biodistribution, and inevitable adverse effects on normal tissues. Tumor‐targeted delivery …
Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence
MK Shanmugam, X Dai, AP Kumar, BKH Tan, G Sethi… - Cancer letters, 2014 - Elsevier
Abstract Oleanolic acid (OA, 3β-hydroxyolean-12-en-28-oic acid) is a ubiquitous pentacyclic
multifunctional triterpenoid, widely found in several dietary and medicinal plants. Natural …
multifunctional triterpenoid, widely found in several dietary and medicinal plants. Natural …
Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective
Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug
targets which have been studied intensively in the past few decades. Although several drugs …
targets which have been studied intensively in the past few decades. Although several drugs …
Discovery and development of natural product oridonin-inspired anticancer agents
Natural products have historically been, and continue to be, an invaluable source for the
discovery of various therapeutic agents. Oridonin, a natural diterpenoid widely applied in …
discovery of various therapeutic agents. Oridonin, a natural diterpenoid widely applied in …
Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor
W Duan, J Li, ES Inks, CJ Chou, Y Jia… - Journal of medicinal …, 2015 - ACS Publications
On the basis of the strategy of creating multifunctional drugs, a novel series of
phenylsulfonylfuroxan-based hydroxamates with histone deacetylase (HDAC) inhibitory and …
phenylsulfonylfuroxan-based hydroxamates with histone deacetylase (HDAC) inhibitory and …
[HTML][HTML] Heavy metal toxicity in plants and the potential NO-releasing novel techniques as the impending mitigation alternatives
Environmental pollutants like heavy metals are toxic, persistent, and bioaccumulative in
nature. Contamination of agricultural fields with heavy metals not only hampers the quality …
nature. Contamination of agricultural fields with heavy metals not only hampers the quality …
Novel hybrids of 3-substituted coumarin and phenylsulfonylfuroxan as potent antitumor agents with collateral sensitivity against MCF-7/ADR
Twenty-three new coumarin-furoxan hybrids were synthesized, which exhibited nanomole
antiproliferation activities in A2780, A2780/CDDP, MCF-7/ADR, and MDA-MB-231. Among …
antiproliferation activities in A2780, A2780/CDDP, MCF-7/ADR, and MDA-MB-231. Among …
Novel nitric oxide-releasing derivatives of brusatol as anti-inflammatory agents: design, synthesis, biological evaluation, and nitric oxide release studies
W Tang, J Xie, S Xu, H Lv, M Lin, S Yuan… - Journal of Medicinal …, 2014 - ACS Publications
Brusatol, a biologically active natural product, was modified in four distinct positions through
the covalent attachment of a furoxan moiety, which acts as a nitric oxide (NO) donor. Forty …
the covalent attachment of a furoxan moiety, which acts as a nitric oxide (NO) donor. Forty …